Preoperative contrast-enhanced computed tomography-based radiomics model for overall survival prediction in hepatocellular carcinoma

doi:10.3748/wjg.v28.i31.4376

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 31

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6004)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series, Tables (1-2) series.

Item

Count

PDF

267

WORD

HTML

3447

Figures (1-7)

437

Tables (1-2)

438

Sum=4641

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

362

Download

1001

Sum=1363

Aug 21, 2022 (publication date) through Feb 8, 2025

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Aug 21, 2022; 28(31): 4376-4389
Published online Aug 21, 2022. doi: 10.3748/wjg.v28.i31.4376

Table 1 The demographic and clinical-pathologic characteristics of patients

Variables	Training cohort (n = 107)	Validation cohort (n = 43)	P value
Age, yr (mean ± SD)	49.77 ± 10.57	50.35 ± 11.43	0.766
Sex (male/female)	94/13	36/7	0.501
Alcohol abuse (present/absent)	44/63	19/24	0.731
Tumor number (multiple/single)	22/85	10/33	0.716
Tumor diameter, cm (> 5/≤ 5)	69/38	24/19	0.322
MVI (present/absent)	46/61	17/26	0.698
Cirrhosis (present/absent)	100/7	36/7	0.123
TNM stage (I-II/III-IV)	54/53	18/25	0.340
BCLC stage (0-A/B-C)	61/46	20/23	0.243
WBC, × 10⁹/L (median, IQR)	6.05 (5.00-7.3)	6.11 (5.04-8.04)	0.290
Platelets, × 10⁹/L (mean ± SD)	190.75 ± 71.91	202.02 ± 79.32	0.401
LYMPH, × 10⁹/L (median, IQR)	1.63 (1.19-1.94)	1.74 (1.35-2.04)	0.229
NEUT, × 10⁹/L (median, IQR)	3.75 (2.68-4.07)	3.90 (2.85-5.17)	0.385
DB, μmol/L (median, IQR)	5.20 (4.20-5.81)	4.85 (3.68-5.56)	0.077
TB, μmol/L (median, IQR)	12.50 (9.43-15.91)	13.38 (8.93-17.11)	0.840
ALB, g/L (mean ± SD)	38.42 ± 4.30	36.87 ± 5.49	0.069
GLB, g/L (median, IQR)	31.80 (28.80-35.28)	32.22 (29.80-35.44)	0.480
GGT, U/L (mean ± SD)	115.26 ± 136.68	105.49 ± 82.44	0.662
ALT, U/L (median, IQR)	31.00 (21.24-44.14)	27.60 (17.46-42.88)	0.306
AST, U/L (median, IQR)	34.50 (26.55-51.51)	35.40 (25.55-46.02)	0.891
AFP, ng/mL (> 200/≤ 200)	50/57	23/20	0.454
HBsAg (positive/negative)	91/16	33/10	0.225
NLR (> 2.31/≤ 2.31)	50/57	21/22	0.815

IQR: Interquartile range; MVI: Microvascular invasion; TNM: Tumor, node and metastasis; BCLC: Barcelona clinic liver cancer; WBC: White blood cell count; LYMPH: Lymphocyte count; NEUT: Neutrophil count; DB: Direct bilirubin; TB: Total bilirubin; ALB: Albumin; GLB: Globulin; GGT: Gamma-glutamyl transpeptidase; ALT: Alanine transaminase; AST: Aspartate transaminase; AFP: Alpha fetoprotein; HBsAg: Hepatitis B surface antigen; NLR: Neutrophil-to-lymphocyte ratio.

Citation: Deng PZ, Zhao BG, Huang XH, Xu TF, Chen ZJ, Wei QF, Liu XY, Guo YQ, Yuan SG, Liao WJ. Preoperative contrast-enhanced computed tomography-based radiomics model for overall survival prediction in hepatocellular carcinoma. World J Gastroenterol 2022; 28(31): 4376-4389
URL: https://www.wjgnet.com/1007-9327/full/v28/i31/4376.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i31.4376